These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 24171820)

  • 1. Respiratory syncytial virus: how, why and what to do.
    Rodriguez R; Ramilo O
    J Infect; 2014 Jan; 68 Suppl 1():S115-8. PubMed ID: 24171820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention.
    Manzoni P; Paes B; Resch B; Carbonell-Estrany X; Bont L
    Early Hum Dev; 2012 May; 88 Suppl 2():S34-41. PubMed ID: 22633511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational sciences approach to RSV vaccine development.
    Kurzweil V; Tang R; Galinski M; Wang K; Zuo F; Cherukuri A; Gasser RA; Malkin E; Sifakis F; Mendel DB; Esser MT
    Expert Rev Vaccines; 2013 Sep; 12(9):1047-60. PubMed ID: 24053398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory syncytial virus prophylaxis and the "special population".
    Mirra V; Ullmann N; Cherchi C; Onofri A; Paglietti MG; Cutrera R
    Minerva Pediatr; 2018 Dec; 70(6):589-599. PubMed ID: 30334623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RSV associated hospitalizations in children in Karachi, Pakistan: Implications for vaccine prevention strategies.
    Ali A; Yousafzai MT; Waris R; Jafri F; Aziz F; Abbasi IN; Zaidi A
    J Med Virol; 2017 Jul; 89(7):1151-1157. PubMed ID: 28092107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Respiratory syncytial virus].
    Seidenberg J
    Internist (Berl); 2019 Nov; 60(11):1146-1150. PubMed ID: 31486858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
    DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
    J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory syncytial virus disease: update on treatment and prevention.
    Krilov LR
    Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospitalization for Respiratory Syncytial Virus Bronchiolitis in the Palivizumab Prophylaxis Era: Need for Reconsideration of Preventive Timing and Eligibility.
    Oz-Alcalay L; Ashkenazi S; Glatman-Freedman A; Weisman-Demri S; Lowenthal A; Livni G
    Isr Med Assoc J; 2019 Feb; 21(2):110-115. PubMed ID: 30772962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia.
    Grimaldi M; Gouyon B; Michaut F; Huet F; Gouyon JB;
    Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Epidemiologic Characteristics of Hospitalized Patients with Laboratory-Confirmed Respiratory Syncytial Virus Infection in Eastern China between 2009 and 2013: A Retrospective Study.
    Cui D; Feng L; Chen Y; Lai S; Zhang Z; Yu F; Zheng S; Li Z; Yu H
    PLoS One; 2016; 11(11):e0165437. PubMed ID: 27802292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory syncytial virus-related bronchiolitis in Puerto Rico.
    Molinari Such M; García I; García L; Puig G; Pedraza L; Marín J; Valcárcel M
    P R Health Sci J; 2005 Jun; 24(2):137-40. PubMed ID: 16116931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom.
    Goddard NL; Cooke MC; Gupta RK; Nguyen-Van-Tam JS
    Epidemiol Infect; 2007 Jan; 135(1):159-62. PubMed ID: 16753078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
    Fitzgerald DA
    Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Guidelines for respiratory syncytial virus prophylaxis. An update].
    Carbonell-Estrany X; Quero Jiménez J
    An Esp Pediatr; 2002 Apr; 56(4):334-6. PubMed ID: 11927077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.